Objectives: To describe the 'Resuscitation with Pre-HospItaL bLood products' trial (RePHILL) -a multi-centre randomised controlled trial of pre-hospital blood product (PHBP) administration vs standard care for traumatic haemorrhage.
. RePHILL trial schema. survival. Various PHBP combinations have been deployed by pre-hospital emergency medical (PHEM) providers (Dalton, 1993; Glassberg et al., 2013; Weaver et al., 2013; O'Reilly et al., 2014a; Sunde et al., 2015; Wales Air Ambulance, 2015; Zielinski et al., 2017) . Although a biological case for the superiority of PHBP resuscitation can be made (Holcomb et al., 2015a) , our group's systematic review of the clinical literature reported that the majority of evidence was of 'very low quality' [as defined by the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) criteria (Kerwin et al., 2012) ] from which no reliable conclusions could be drawn (Smith et al., 2016) . Recently released UK national guidelines for trauma management (National Institute for Health and Clinical Excellence, 2016) did not examine any pre-hospital transfusion studies. Instead, pre-hospital guidance was extrapolated from one in-hospital cohort study of patients receiving 10 units of RBC in the first 24 h after admission (Neal et al., 2012) .
' A Multi-Centre Randomised Controlled Trial of Pre-Hospital Blood Product Administration vs Standard Care for Traumatic Haemorrhage' (abbreviated title: 'Resuscitation with Pre-HospItaL bLood products' or 'RePHILL') is a randomised controlled trial (RCT), which will investigate the hypothesis that pre-hospital administration of up to two units each of RBC and lyophilised (freeze-dried) plasma (LP) will improve tissue perfusion (as measured by lactate clearance) and reduce mortality in trauma patients with haemorrhagic shock compared to the current practice of the majority of UK PHEM services of crystalloid resuscitation.
MATERIALS AND METHODS

Trial design
This study is a multi-centre, two-arm, parallel group, open-label, interventional phase III RCT of 490 patients. An internal pilot phase was included to validate trial logistics. The trial schema is shown in Fig. 1 . This protocol conforms to the SPIRIT guidelines (Chan et al., 2013) (Appendix S1). The pilot phase began recruitment in December 2016, with approval to continue into (Regnier et al., 2012) Lactate clearance = 100 ×
[Lactateinitial]− [Lactateinterval] [Lactateinitial]×Interval Lactate clearance is measured in %/h. Lactate concentrations are measured in mmol/L. Interval is measured in hours. If the interval lactate concentration is within the normal range, the patient will be deemed to have cleared ≥20%/h. If the patient dies prior to the interval sample being collected, they will be assumed to have failed to clear ≥20%/h for the purpose of analysing lactate clearance alone as a secondary outcome.
the main trial received in June 2017. Recruitment is expected to continue until 2020.
Trial objectives
Primary objective. The principal objective of RePHILL is to investigate the clinical effectiveness of PHBP resuscitation compared with the current standard care of restricted crystalloid-based resuscitation in participants suffering from major traumatic haemorrhage.
Secondary objectives.
To test the hypotheses that, compared to standard care, PHBP resuscitation:
1. improves blood pressure, heart rate and capillary oxygenation on arrival to the Emergency Department (ED); 2. does not prolong pre-hospital time; 3. reduces pre-hospital fluid requirements; 4. reduces in-hospital transfusion requirements; 5. reduces trauma-induced coagulopathy; 6. preserves platelet function; 7. does not lead to a greater incidence of transfusion-related complications, particularly acute respiratory distress syndrome (ARDS); 8. does not lead to significant blood product wastage.
Outcomes
Primary outcome. The primary outcome is a composite measure consisting of episode mortality (death from all causes between trial entry and discharge from the primary receiving facility to non-acute care) and failure to achieve lactate clearance of ≥20%/h over the first 2 h after randomisation. Regnier et al. (2012) studied this endpoint, reporting that mortality among such patients is approximately 20%, similar to the 23% mortality in trauma patients with a comparable degree of hypotension to those eligible for RePHILL (Hasler et al., 2011 (Hasler et al., , 2012 . Lactate clearance is thus a clinically meaningful biochemical predictor of outcome, but subject to minimal confounding from in-hospital interventions. Episode mortality Failure to achieve lactate clearance ≥20%/h in the 2 h after randomisation All-cause mortality within 3 h and within 30 days of randomisation Pre-hospital time Pre-hospital fluid type and volume Vital signs (SBP, heart rate, capillary oxygen saturation) at scene, on arrival at ED, then also at 2, 6, 12 and 24 h after arrival at ED Venous lactate concentration on arrival at ED and at 2 h after arrival at ED Trauma-induced coagulopathy (defined as international normalised ratio (INR) >1.5) to be measured on arrival at ED, and also at 2 and 6 h after arrival at ED. Coagulation measured viscoelastically by rotational thromboelastometry (ROTEM ® ) on arrival at ED 1 Platelet function using multiple electrode impedence aggregometery (MultiPlate ® ) on arrival at ED 1 Total blood product receipt at 6, 12 and 24 h after arrival at ED ARDS occurring within the first 7 days after injury Transfusion-related complications Organ failure-free days (Chase et al., 2010) 2 ARDS, acute respiratory distress syndrome; ED, emergency department. 1 Selected sites only. 2 Organ failure defined as any sequential organ failure assessment component ≥3 (Vincent et al., 1996) . Organ failure assumed to be absent if participant discharged from hospital, and assumed to be present if the participant has died.
Sample size calculation
Although no definitive data exists on this composite outcome, observational studies suggest potentially dramatic reductions in mortality from civilian pre-hospital RBC (Brown et al., 2015b) and military pre-hospital RBC combined with thawed plasma (O'Reilly et al., 2014b) . Following consultation with experts in pre-hospital trauma resuscitation, it is considered that an absolute reduction of 10% in the proportion of patients experiencing one of the primary outcome components is clinically meaningful and is an appropriate effect size upon which to base the power calculation.
To detect an absolute difference of 10% between groups in the proportion of patients experiencing either component of the primary outcome (i.e. from 20% in the standard care group to 10% in the group receiving PHBP) using the method of difference between proportions (two-sided Fisher's exact test) with 80% power, and a type 1 error rate of 5% (i.e. = 0.05), requires 438 participants. Allowing and adjusting for a 10% loss to follow-up, 490 participants are required.
Setting
The study takes place in three regional major trauma networks in UK (West Midlands, East Midlands, East of England) . These networks consist of integrated National Health Service 
Eligibility criteria
Entry criteria for RePHILL participants are listed in Table 3 .
Trial interventions
All trial-specific processes were designed to minimise any prolongation of pre-hospital time.
Experimental intervention. The trial intervention is up to two units of RBCs (blood group O RhD negative, Kell negative) and two units of LyoPlas N-w (blood groups A or AB; DRK-Blutspendedienst West, Ratingen, Germany) (see Source of blood products), delivered as single-unit boluses in the following sequence: one unit RBC, one unit LyoPlas N-w, one unit RBC, one unit LyoPlas N-w. This sequence was chosen as the most efficient, allowing the first unit of RBC to be delivered while LyoPlas N-w is being reconstituted. Both LyoPlas N-w units in single intervention will be of the same blood group.
Control intervention.
The control intervention is up to four 250 mL boluses of 0.9% saline. This was chosen because it is the most common crystalloid used by the PHEM services in the UK for trauma resuscitation (D. Naumann et al., unpublished data) . This allows comparison of PHBP against existing standard care. The average volume of one unit of RBC is approximately 270 mL (range: 220-340 mL), while reconstituted Lyoplas N-w is 213 mL. Thus one unit each of RBC and LP have a comparable volume to two saline boluses.
Delivery of interventions.
Participants receive up to four boluses of the assigned intervention to restore and maintain systolic blood pressure (SBP) ≥90 mmHg or a palpable radial pulse. This is assessed after each bolus. If SBP is restored before all intervention boluses are administered, but subsequently falls, interventions continue from the point at which delivery was paused. All interventions should be administered through fluid warmers and may be administered by intravenous or intraosseous route. If additional fluid is required to maintain blood pressure, further 250-mL boluses of 0.9% saline may be given according to normal local practice. All other pre-hospital and in-hospital care proceeds as directed by the treating clinicians.
Practical considerations leading to the choice of 1 : 1 blood product ratio. Various factors lead to the selection of a combination of RBC and LP as the trial intervention. Optimum blood product ratios remain a matter of debate. The Prospective Observational Multicentre Major Trauma Transfusion Cohort Study found that failure to achieve plasma or platelet : RBC ratios of at least 1 : 2 during the first 6 h from admission was associated with significantly higher mortality than among patients who received at least 1 : 1 . In contrast, the Pragmatic Randomised Optimal Platelet and Plasma Ratios RCT found no difference in overall mortality between plasma, platelets and RBCs administered in a ratio of 1 : 1 : 1 donor units compared to 1 : 1 : 2 (Holcomb et al., 2015b) . In observational studies, hospital-based administration of plasma within the first six units of blood products is associated with a 66% reduction in the odds ratio for 30-day mortality . Pre-hospital administration of 1 : 1 ratios of thawed plasma and RBC to battlefield casualties has been associated with a 58% reduction in mortality compared to historical injury-matched controls (O'Reilly et al., 2014b) . Plasma : RBC ratios of 1 : 1 are perceived as offering the maximum possible benefit. RePHILL seeks to deliver this from as close to the time of injury as possible.
Rationale for LP rather than fresh frozen plasma. Various approaches to the delivery of plasma in the field have been described. Fresh frozen plasma (FFP) can be carried by ground ambulance for rapid on-site thawing (Moore et al., 2015) , but requires custom-made packaging and significant investment in equipment for each ambulance installation. Pre-thawed plasma is suitable for situations where the PHEM team deploy from a base close to the blood bank and where unused product can be rotated back into stock with an expectation use before expiry to avoid wastage. This logistic model was used by the UK Defence Medical Services in Afghanistan, based around a 5-day post-thaw shelf-life (O'Reilly et al., 2014a) . A similar approach in a US civilian study reported less than 2% wastage of blood products (Holcomb et al., 2015a) . UK regulations at the time of trial design limited the post-thaw shelf-life of FFP to 24 h (this post-thaw period was extended to 5 days in 2016). UK civilian PHEM teams typically deploy by helicopters based at airfields remote from medical facilities. Given the relative infrequency of exsanguinating trauma in the UK, reliance on pre-thawed plasma might be unacceptably wasteful. In contrast, LP can be stored at room temperature for up to 15 months and reconstituted for use in as little as 5 min. Its suitability for the pre-hospital environment is demonstrated by the Israeli military's decision to replace pre-hospital crystalloid with LP as the resuscitation fluid of choice (Glassberg et al., 2013) . The French military use a French-produced LP as its sole plasma product on operations (Sailliol et al., 2013) , while the UK Defence Medical Services introduced LyoPlas N-w for remote operations in 2012 (Gokhale et al., 2016) . Norwegian civilian helicopter emergency medical services have carried LP since 2013 (Zielinski et al., 2017) .
Source of blood products. LyoPlas N-w is a LP manufactured by the German Red Cross. Individual units are manufactured from single donations. It is licensed in Germany (licence no. PEI.H.03075.01.1) for the same indications as FFP. Approval for the import and use of LyoPlas N-w as an Investigational Medical Product for the purposes of this trial was granted by the UK Medicines and Healthcare Regulatory Authority (MHRA).
The RBC used in RePHILL are blood group O, RhD negative, Kell negative, leucodepleted RBC in saline, adenine, glucose and mannitol (SAG-M) additive solution, drawn from NHS blood and transplant stocks supplied by the blood banks that are supporting the trial. A summary of standard collection and processing is included in Appendix S2, Supporting Information.
Regulatory framework. The MHRA considers LyoPlas N-w to be a pharmaceutical, rather than a blood product in view of the post-donation processing (Joint UKBTS/NIBSC Professional Advisory Committee, 2010). RePHILL is conducted in accordance with the amended Clinical Trials Regulations (2004; 2006) , Good Clinical Practice (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1996) and the Declaration of Helsinki (World Medical Association, 2013) .
Randomisation
Randomisation is performed by a computer programme at the Trial Coordinating Centre -the Birmingham Clinical Trials Unit (BCTU). Participants are randomised at the level of the individual in a 1 : 1 ratio to either PHBP resuscitation or crystalloid resuscitation. The randomisation procedure is stratified by Intervention Delivery Site (IDS) to account for variation in type of trauma and the care provided between sites.
Nominated personnel at each blood bank obtain randomised allocations through a secure online randomisation system (accessible 24 h/day). Blood banks are supplied with pre-printed 'treatment box number' labels. The allocated trial intervention is then packed in transport boxes, secured with tamper-proof seals and labelled with the specified box numbers.
Pre-recruitment blinding
Each intervention is issued in two sealed, thermally stable transport boxes (conditioned for the different storage requirements of RBC and LP), labelled with the same 'treatment box number' as issued by the Trial Coordinating Centre. For crystalloid interventions, each box contains two 250 mL 0.9% saline. For PHBP interventions, one container contains two units of RBCs, the other contains two units of LyoPlas N-w. Additional weight is added to boxes containing crystalloid to ensure that the intervention cannot be predicted by box weight. Sealed and numbered transport boxes are delivered to PHEM services by courier. These remain sealed until after a decision has been made to enter a patient into the trial. Only one intervention is carried at a time. This removes any need for the PHEM team to contact the Trial Coordinating Centre during the pre-hospital phase, which would both delay treatment and risk loss to recruitment if communications could not be established.
To ensure that pre-recruitment blinding is maintained, the integrity of seals is subject to 100% audit on the return of unused interventions. This also confirms that interventions have been kept in the appropriate conditions and that no tampering has taken place.
Patient randomisation, enrolment and lactate measurement
The PHEM doctor assesses the potential participant's vital signs on scene and confirms if eligible for entry into the RePHILL trial. If they fulfil the eligibility criteria, a capillary blood lactate concentration is measured and the treatment boxes opened. The randomised study intervention is revealed and given to the patient. Participants are considered entered into the trial when the PHEM team open the first treatment box.
Eligibility is documented at the Receiving Hospital Site, and the participant is enrolled into the trial and assigned a trial number. Participants who are later found to be ineligible, but who have received the trial interventions will remain in the trial as per protocol and included in the analysis, if they consent to this.
Venous lactate concentration is measured on arrival at ED as part of a standard trauma admission blood draw. A further venous lactate will be drawn 2 h after arrival at the ED as part of RePHILL.
Consent
Legal framework for research in patients lacking capacity. As the occurrence of major trauma is unpredictable and immediately incapacitating, prospective informed consent from participants is not possible. In the rare event that a participant retains capacity at trial entry, their clinical condition will require immediate resuscitation. It would be inappropriate to delay life-saving treatment and transport in order to seek informed consent. UK legislation permits emergency care research to begin in such contexts (Clinical Trials Regulations 2004 (as amended); Human Tissue Act, 2004 (as amended) ) and has been applied in the PARAMEDIC-2 RCT of adrenaline in out-of-hospital cardiac arrest (Perkins et al., 2015, p. 17) . Details of the relevant legislation are provided in Appendix S2.
Consent in RePHILL.
Consent to continue in RePHILL is sought at the earliest appropriate opportunity. In practical terms, this consent is to continue data collection as most trial processes will have occurred prior to any opportunity to seek informed consent from a participant or appropriate representative. Initial consent is usually sought from a professional legal representative shortly after arrival at the receiving hospital, as it is rare for either the participant to retain capacity at this time, or for a personal legal representative to be available. As with PARAMEDIC-2, this is deemed to be at a point when the participant is no longer critically ill. An approach to patient or personal legal representative can then be made at a time when they are better able to retain and consider information.
The most challenging ethical consideration in this trial relates participants who die prior to consent being obtained. RePHILL employs a passive information approach, consistent with previous and ongoing emergency care studies (Perkins et al., 2015) , placing information in locations likely to be visited by relatives of the deceased. The information contains a brief summary of the trial and contact details for those wishing further information. Further details of the rationale for this approach are provided in Appendix S2.
Jehovah's Witnesses. Jehovah's Witnesses hold beliefs which prohibit the receipt of blood transfusions. Normal trauma resuscitation practice in emergency departments (EDs) and among PHEM teams currently delivering PHBP is to search for an Advance Medical Directive (AMD) identifying a patient as a Jehovah's Witness prior to the administration of blood products. Clinicians involved in RePHILL perform the same rigorous checks in the pre-hospital environment, prior to recruitment. Liaison with representatives of the Hospital Liaison Committees for Jehovah's Witnesses and national Jehovah's Witnesses Hospital Information Services took place during trial design and implementation to ensure that information regarding RePHILL was communicated to potentially affected communities.
Additional trial procedures and assessments
The standard admission blood draw on ED arrival includes full blood count, prothrombin time and international normalised ratio. Transfusion measures include blood grouping and assessment of mixed-field blood groups. Selected sites will also assess coagulation by viscoelastic methods (ROTEM™, Tem International GmbH, Munich, Germany) and platelet function (MultiPlate™, Roche Diagnostics International Ltd, Rotkreuz, Switzerland). Other assessments are summarised in Table 2 . Data collection ends at the earliest of discharge from the acute care facility, death or 30 days, unless consent is withdrawn earlier. Mortality data will continue to be collected for participants who remain in an acute care facility beyond 30 days.
Safety considerations
The additional risk to participants in RePHILL is considered to be minimal. As discussed above, 'standard care' recipients receive treatment identical to that which they would receive outwith the trial, whereas PHBP recipients receive treatment equivalent to that which they would receive on arrival at an ED.
Transfusion safety. The plasma from which LyoPlas N-w is produced is filtered, rendering it 'virtually cell-free'. LyoPlas N-w is produced only from leucocyte-antibody negative plasma, minimising risk of transfusion-related acute lung injury (DRK-Blutspendedienst West, 2017) . LP transfusion is safe, with no reported transfusion reactions associated with French LP (Martinaud et al., 2011) or the previous German mini-pool LP (Schoenfeld et al., 2010) , while the incidence of transfusion reactions associated with LyoPlas N-w is no different from that of FFP (Bux et al., 2013; DRK-Blutspendedienst West, 2017) . Systematic review of PHBP resuscitation for trauma identified only two potential pre-hospital transfusion reactions, both associated with RBC transfusion, among 759 PHBP recipients (Smith et al., 2016) . A third potential event (associated with LyoPlas N-w) was reported subsequently (Shlaifer et al., 2017) in a cohort of 109 recipients. A true transfusion reaction was considered the most likely explanation in only of these (associated with pre-hospital RBC transfusion). In contrast, UK haemovigilance monitoring reports the rate of allergic, hypotensive or severe febrile reactions to FFP as one per 721 units issued (Bolton-Maggs et al., 2016) .
LyoPlas N-w is produced by a quarantined single donor process; plasma is processed only if a donor retests negative for blood-borne pathogens at least 4 months after the donation was received, thus minimising the risk of blood borne virus transmission (Bux et al., 2013) . Based on previous national modelling (Advisory Committee on the Safety of Blood, Tissues and Organs, 2013), transmission of prion disease (particularly variant Creutzfeld-Jakob disease) is not considered a hazard of this study (for full discussion, see Appendix S2.).
Transfer delay. Delivering PHBP has the potential to incur a delay in transfer to definitive haemorrhage control, increasing risk to patients. This is reported as a secondary outcome and is one of the safety considerations to be monitored by the Data Monitoring and Ethics Committee (DMEC).
Adverse event reporting
Adverse events will be reported in accordance with statute (Clinical Trials Regulations, 2004) , using standard definitions of events and causality. Given the high mortality and morbidity anticipated in a major trauma population, certain serious adverse events (SAEs) are exempt from expedited reporting (Table 4) . SAEs relating to a pre-existing condition will not be reported.
The inclusion of RBC as a component of the intervention mandates compliance with normal haemovigilance requirements. Transfusion-related adverse events are to be reported to both the coordinating blood bank for the relevant IDS and through the serious hazards of transfusion and serious adverse blood reactions and events (SHOT/SABRE) in accordance with the EU Blood Safety Directive (2005).
Internal pilot phase
RePHILL successfully completed an internal pilot phase to assess trial logistics, validate the multi-centre aspects of the trial and confirm that it was both feasible and practical to continue to recruit into the main trial. The following targets for the pilot phase were set to justify progression to the main trial:
• Minimum of 25 participants recruited across at least two active sites; • In participants recruited to the trial intervention arm, at least one unit of RBC and one unit of LP delivered to at least 80% of participants before reaching hospital; • At least 90% data captured;
• DMEC have no safety concerns which would prohibit continuation to the main trial.
Statistical methods
The primary comparison will be those randomised to resuscitation with PHBP vs those randomised to resuscitation with 0.9% saline (standard care). All primary analyses will be based on the intention-to-treat principle. For all major outcome measures, summary statistics and differences between groups (e.g. mean differences, relative risks, hazard ratios) will be presented with 95% confidence intervals (CIs) and P-values from two-sided tests also given. Outcomes will be adjusted for the stratification variable, IDS, where possible. A P-value <0.05 will be considered statistically significant. No adjustment for multiple comparisons will be made.
Primary outcome analysis.
The primary outcome is a binary composite measure of episode mortality and early lactate clearance. A relative risk and 95% CI will be calculated using log-binomial regression modelling. Individual components will also be reported in accordance with the recommendations of Ferreira-Gonzalez et al. (2007) .
Secondary outcome analysis. Dichotomous data (e.g. development of ARDS, mortality at specified time points) will be analysed in the same way as the primary outcome. Mortality will also be analysed using the log-rank test with a Cox proportional hazard model used to calculate hazard ratios. Continuous outcomes (e.g. pre-hospital fluid volumes, vital signs) will be analysed at specified time points using linear regression models, with mean differences and 95% CIs reported.
Subgroup analyses. Eleven a priori subgroup analyses are planned with respect to the primary outcome measure (Table 5) . Tests for statistical heterogeneity (e.g. by including the treatment group by subgroup interaction parameter in the regression model) will be performed prior to any examination of effect estimates within subgroups. The results of subgroups will be treated with caution and will be used for the purposes of hypothesis generation only.
Missing data and sensitivity analyses. Every attempt will be made to collect full follow-up data on all study participants; it is thus anticipated that missing data will be minimal. Participants with missing primary outcome data will not be included in the primary analysis in the first instance. This presents a risk of bias, and sensitivity analyses will be undertaken to assess the possible impact of the risk. Missing responses will be simulated using a Markov chain Monte Carlo method (MCMC) to generate multiple data sets. Analysis will be then be performed on each set with the results combined using Rubin's rule to obtain a single set of results (treatment effect estimate and CIs). Any sensitivity analyses will not, irrespective of their differences, supplant the planned primary analyses.
Data monitoring and ethics committee (DMEC)
An independent DMEC has been established to oversee the safety of participants in the trial. The DMEC met prior to the trial opening to enrolment and after the internal pilot phase to assess the safety data and advised on continuation to the main phase III trial. The DMEC will now meet at least annually. Interim analyses of major outcome measures and safety data will be conducted and provided in strict confidence to the DMEC, which will consider whether the accumulated data from the trial, together with the results from other relevant research, justifies continued recruitment of further participants. The DMEC operates in accordance with a trial specific charter.
Registration, Approvals and Funding
RePHILL is registered with the ISRCTN registry (ISRCTN62326938) and with EudraCT (2015-001401-13 
Dissemination
The trial results will be reported in accordance with the CON-SORT guidelines (Schulz et al., 2011) and will be submitted for publication in peer-reviewed journals and presentation at appropriate national and international academic meetings. Trial participants will be sent a summary of the final results, including references to full papers. RePHILL data may be made available to external groups wishing to undertake original analysis, subject to approval from the Trial Management Group.
DISCUSSION
Early blood product transfusion and reduced crystalloid administration has been associated with improved survival in observational, predominantly retrospective, military and civilian studies (Murad et al., 2010; Rajasekhar et al., 2011; Bhangu et al., 2013) . Projection of blood products into the pre-hospital phase of trauma care is intuitively attractive; however, the use of PHBP is both logistically challenging and resource intensive, and is not without risk (Bolton-Maggs, 2015) . The most significant and immediate risk of ABO incompatibility may be managed by use of 'universal components'. This, however, has implications for resource management. Although 'universal' plasma donors (group AB) constitute only 4% of the UK donor pool (NHS Blood and Transplant, 2014) , low anti-B titre group A pre-thawed FFP is more available and is an established source of emergency plasma transfusions in patients of unknown ABO group in North American Trauma Centres (Dunbar et al., 2016) . The success and safety of this approach has been reflected in recently published UK guidelines (Hunt et al., 2015) . However, this represents a logistical challenge for helicopter-based services, which frequently deploy from airfields remote from the blood banks that support them. Alternative forms of plasma with longer shelf-lives need to be considered, such as the LP used in RePHILL. In addition, provision of an adequate supply of 'universal' group O RhD negative red cell concentrates (drawn from only 8% of the UK donor pool) remains challenging. Group O RhD negative, Kell negative red cell concentrates should ideally be reserved for female recipients of child-bearing age (Hunt et al., 2015) . Such resource management is impractical in the pre-hospital environment due to the constraints on space and weight inherent in helicopter-based service. Hypothetically, early 'haemostatic' resuscitation might reduce overall transfusion requirements, thus preserving blood products stocks. However, no such benefit has been demonstrated to date (Smith et al., 2016) .
A convincing case for PHBP that justifies utilisation of scarce universal donor resources cannot be made from the published literature, with only 'low' and 'very low' quality evidence, derived from entirely observational studies (predominantly retrospective case series) (Smith et al., 2016) . More recent retrospective military data found an association between a directive mandating pre-hospital helicopter evacuation of critically injured battlefield casualties within 60 min of wounding and a reduction in mortality (Kotwal et al., 2016) . One component of this may have been the delivery of PHBP. However, in common with the majority of studies in this field, missing data and potential confounding was such that the 'influence on morbidity and mortality could not be reliably measured'.
Experts in the field have called for 'prospective studies … to clarify the role of [freeze-dried plasmas] and RBCs in civilian prehospital hemorrhagic shock resuscitation' (Sunde et al., 2015) and have stressed the importance of 'high-quality prospective … data collection' (Jenkins et al., 2014b) . A prospective observational study recently reported no evidence of superiority of PHBP in reducing mortality, but was limited by significant differences in trauma burden and physiology between patients retrieved by PHBP-capable services compared to those transported without access to PHBP . The authors concluded that 'large, multicentre randomized studies [are] required'.
Five PHBP RCTs have attempted to meet this need. Two have terminated early (Shackelford, 2017) due to futility (Control Of Major Bleeding After Trauma -COMBAT) (Moore et al., 2015) or insufficient recruitment (Pre-Hospital Use of Plasma for Traumatic Haemorrhage -PUPTH) (Reynolds et al., 2015) . Other than RePHILL, ongoing studies include the Pre-hospital Air Medical Plasma study (PAMPer) (Brown et al., 2015a) and the Pre-hospital Administration of Lyophilized Plasma for Post-traumatic Coagulopathy Treatment (PREHO-PLYO) (Jost & Lanoe, 2017) . PAMPer compares two units of thawed plasma against standard care in a US trauma population and aims to recruit 530 patients. PREHO-PLYO is a smaller French study of 140 patients investigating the effect of LP on coagulation. The study size calculations for RePHILL and PAMPer are broadly similar. However, PAMPer seeks to detect a 67% relative reduction from a baseline of 22% 30-day mortality, whereas RePHILL's inclusion of a measure of resuscitation efficacy in the composite primary outcome allows assessment of a more modest treatment effect with greater focus on that part of the patient's trauma journey most likely to be affected by pre-hospital intervention. In addition, mechanisms of injury differ between the United States and UK; PAMPer is likely to recruit a higher proportion of penetrating trauma victims, whereas a preponderance of blunt trauma is anticipated among RePHILL participants. Thus PAMPer and RePHILL are complementary studies that have the potential to increase knowledge of the response to trauma resuscitation across a spectrum of injury.
CONCLUSIONS
RePHILL provides a timely and unique opportunity to generate high-quality evidence regarding the efficacy of PHBP resuscitation for trauma patients. Patient-centred outcome measures include survival and morbidity. Physiological and coagulation studies will add to understanding of the mechanisms underlying trauma resuscitation. Logistic considerations will aid future service planning if a benefit to patients is demonstrated.
The RePHILL trial opened to recruitment in December 2016. In June 2017, the funder (NIHR Efficacy and Mechanism Evaluation) confirmed successful completion of the pilot phase and agreed that the trial could progress into the main Phase III RCT. As of 01 August 2017, 34 patients had been recruited.
